A pharma company with several approved brands with large market share was developing a new Crohn’s disease drug. The company partnered with MMIT to determine whether the new drug would be approved in the marketplace
P&T Session Atopic Dermatitis: MMIT recently held a syndicated simulated P&T session focused on the approvals of ruxolitinib cream (Opzelura), lebrikizumab, and tralokinumab for atopic dermatitis.
P&T Session NSCLC: Syndicated IDN P&T session focused on the entry of two new medications; capmatinib (Tabrecta) from Novartis, and tepotinib from Merck. Indicated for the treatment of adult patients with METex14 skipping mutation NSCLC.
Description
